Toxicities associated with 1-month treatment with propylthiouracil (PTU) and methimazole (MMI) in male rats.
Thionamides such as propylthiouracil (PTU) and methimazole (MMI) have been used for more than 50 years to treat the more common causes of thyrotoxicosis/hyperthyroidism such as Graves' disease. Serious adverse effects associated with thionamides in humans include idiosyncratic liver damage, agranulocytosis, aplastic anemia, and vasculitis. Both prospective and retrospective clinical studies with these drugs have failed to identify predictive biomarker for these adverse effects. To assess whether rat is a good model for predicting drug-related adverse events in the liver and in the bone marrow, we conducted a comprehensive study in male rats with multiple doses of PTU and MMI. As expected, euthyroid animals became hypothyroid along with several secondary changes associated with hypothyroidism. There were slight reductions in red blood cell parameters along with some marginal effects on the bone marrow elements. However, there was no evidence of significant neutropenia and liver injury in both PTU-treated and MMI-treated cohorts. MMI-related effects were noted in the seminiferous tubules of the testes. Overall, 1-month daily treatment of euthyroid rats with PTU or MMI resulted in hypothyroidism, minor bone marrow effects, and several secondary effects associated with hypothyroidism, but without any evidence of adverse effects reported in humans including liver injury and agranulocytosis.
Pfizer Inc., Groton, Connecticut, USA Both Prashant R. Nambiar and Gopinath S. Palanisamy contributed equally to the article. Prashant.Nambiar@pfizer.com.
Prashant R
PR
Nambiar
Pfizer Inc., Groton, Connecticut, USA Both Prashant R. Nambiar and Gopinath S. Palanisamy contributed equally to the article.
Gopinath S
GS
Palanisamy
Pfizer Inc., Groton, Connecticut, USA.
Carlin
C
Okerberg
Pfizer Inc., Groton, Connecticut, USA.
Angela
A
Wolford
Pfizer Inc., Groton, Connecticut, USA.
Karen
K
Walters
Pfizer Inc., Cambridge, Massachusetts, USA.
Leonard
L
Buckbinder
Pfizer Inc., Groton, Connecticut, USA.
William J
WJ
Reagan
D000818:Animals; D008297:Male; D008713:Methimazole / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics / Q000633:toxicity*; D011441:Propylthiouracil / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics / Q000633:toxicity*; D051381:Rats; D017208:Rats, Wistar; D013737:Testis / Q000737:chemistry / Q000187:drug effects* / Q000473:pathology; D013961:Thyroid Gland / Q000737:chemistry / Q000187:drug effects* / Q000473:pathology; D018675:Toxicity Tests
D008713:Methimazole; D011441:Propylthiouracil
male endocrine system; methimazole; propylthiouracil; rat pathology; rodents; thyroid toxicity; toxicity; toxicology.